NCT01929863 - Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2013

Primary Completion Date

November 1, 2013

Study Completion Date

November 21, 2013

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

GSK2330672

GSK2330672 will be supplied as oral solution, and will be administered BID \[45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period\]

DRUG

Placebo

GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)

DRUG

Metformin

Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2

Trial Locations (1)

33169

GSK Investigational Site, Miami